secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARROW, INC. (HROW)
CIK:        0001360214
Form:       8-K
Filed at:   2022-12-14T23:59:59+00:00
Accession:  0001493152-22-035372
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harrow buys exclusive U.S. rights to five Novartis ophthalmic drugs for $130M upfront
--------------------------------------------------------------------------------

- Deal: $130M upfront plus up to $45M milestone on TRIESENCE commercial availability; Q1 2023 close subject to HSR clearance.
- Products: ILEVRO, NEVANAC, VIGAMOX, MAXIDEX, TRIESENCE – FDA-approved for cataract surgery, infection, inflammation, and vitrectomy.
- During ~6-month NDA transfer, Novartis continues sales and remits net profit to Harrow; thereafter Harrow controls U.S. market.
- 2023 guidance: net revenue $135-143M, adjusted EBITDA $44-50M, with both expected to ramp in 2024+.
- CEO calls it a landmark transaction that positions Harrow as a leader in the U.S. ophthalmic pharmaceuticals market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1360214/000149315222035372/0001493152-22-035372-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1360214/000149315222035372/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-035372

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer